Epoetin beta biosimilar - CinnaGen

Drug Profile

Epoetin beta biosimilar - CinnaGen

Alternative Names: Beta erythropoietin; CinnaPoietin; rec Hu-EPO beta; rec Hu-erythropoietin beta

Latest Information Update: 05 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CinnaGen
  • Class Antianaemics; Colony-stimulating factors; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 19 Jul 2017 CinnaGen completes a phase III trial for Anaemia in Iran (SC) (IV) (IRCT201601156135N6)
  • 01 Mar 2016 CinnaGen initiates enrolment in a phase III trial for Anaemia in Iran (SC) (IV) (IRCT201601156135N6)
  • 31 Dec 2013 Launched for Anaemia in Iran (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top